Publication

Physical fatigue characterises patient experience of primary Sjogren's syndrome

Arends, S., Meiners, P., Moerman, R. V., Kroese, F. G. M., Brouwer, L., Spijkervet, F. K. L., Vissink, A. & Bootsma, H., 2017, In : Clinical and Experimental Rheumatology. 35, 2, p. 255-261 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Arends, S., Meiners, P., Moerman, R. V., Kroese, F. G. M., Brouwer, L., Spijkervet, F. K. L., ... Bootsma, H. (2017). Physical fatigue characterises patient experience of primary Sjogren's syndrome. Clinical and Experimental Rheumatology, 35(2), 255-261.

Author

Arends, S. ; Meiners, P. ; Moerman, R. V. ; Kroese, F. G. M. ; Brouwer, Liesbeth ; Spijkervet, F. K. L. ; Vissink, A. ; Bootsma, H. / Physical fatigue characterises patient experience of primary Sjogren's syndrome. In: Clinical and Experimental Rheumatology. 2017 ; Vol. 35, No. 2. pp. 255-261.

Harvard

Arends, S, Meiners, P, Moerman, RV, Kroese, FGM, Brouwer, L, Spijkervet, FKL, Vissink, A & Bootsma, H 2017, 'Physical fatigue characterises patient experience of primary Sjogren's syndrome', Clinical and Experimental Rheumatology, vol. 35, no. 2, pp. 255-261.

Standard

Physical fatigue characterises patient experience of primary Sjogren's syndrome. / Arends, S.; Meiners, P.; Moerman, R. V.; Kroese, F. G. M.; Brouwer, Liesbeth; Spijkervet, F. K. L.; Vissink, A.; Bootsma, H.

In: Clinical and Experimental Rheumatology, Vol. 35, No. 2, 2017, p. 255-261.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Arends S, Meiners P, Moerman RV, Kroese FGM, Brouwer L, Spijkervet FKL et al. Physical fatigue characterises patient experience of primary Sjogren's syndrome. Clinical and Experimental Rheumatology. 2017;35(2):255-261.


BibTeX

@article{efbcefcee3bc4e7083beea02a62dcade,
title = "Physical fatigue characterises patient experience of primary Sjogren's syndrome",
abstract = "ObjectiveBesides ocular and oral dryness, fatigue is a major symptom in patients with primary Sjogren's syndrome (pSS). Our aim was to investigate the importance of fatigue in relation to other symptoms experienced as well as to evaluate the effect of rituximab treatment on fatigue in pSS patients with active disease.MethodsThis analysis was based on data from our open-label rituximab study in 28 pSS patients. Symptoms of dryness, physical fatigue, pain, and mental fatigue were scored on 0-10 scales (according to ESSPRI). Systemic disease activity was assessed with ESSDAI.ResultsAt baseline, 24 (86{\%}) patients rated physical fatigue as the complaint most eligible for improvement (median importance of 10), followed by pain, dryness, and mental fatigue. After rituximab treatment, physical fatigue showed maximum improvement of 2.5 points and 31{\%} in median values at group level, and 10 (36{\%}) patients reached physical fatigue score<5 representing patient-acceptable symptom state (PASS). In comparison, systemic disease activity improved 5.5 points and 73{\%} at group level, and 22 (79{\%}) patients reached ESSDAI<5 representing low disease activity. GEE analysis over time revealed that physical fatigue was significantly associated with absolute number of B cells, dryness and mental fatigue, but not with ESSDAI, IgG levels and IgM-RF.ConclusionPhysical fatigue characterises patient experience of pSS. Rituximab treatment resulted in significant improvement of patient-reported symptoms. However, the large majority of patients still experienced physical fatigue at an unsatisfactory level, above the cut-off value for PASS. Therefore, attention for optimal management of this prominent symptom is warranted.",
keywords = "primary Sjogren's syndrome, fatigue, patient-reported outcome, rituximab, patient-acceptable symptom state, CELL DEPLETION THERAPY, QUALITY-OF-LIFE, REPORTED INDEX, CLINICAL-TRIAL, DOUBLE-BLIND, DISEASE, DISABILITY, RITUXIMAB, ESSPRI, IMPROVEMENT",
author = "S. Arends and P. Meiners and Moerman, {R. V.} and Kroese, {F. G. M.} and Liesbeth Brouwer and Spijkervet, {F. K. L.} and A. Vissink and H. Bootsma",
year = "2017",
language = "English",
volume = "35",
pages = "255--261",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "CLINICAL & EXPER RHEUMATOLOGY",
number = "2",

}

RIS

TY - JOUR

T1 - Physical fatigue characterises patient experience of primary Sjogren's syndrome

AU - Arends, S.

AU - Meiners, P.

AU - Moerman, R. V.

AU - Kroese, F. G. M.

AU - Brouwer, Liesbeth

AU - Spijkervet, F. K. L.

AU - Vissink, A.

AU - Bootsma, H.

PY - 2017

Y1 - 2017

N2 - ObjectiveBesides ocular and oral dryness, fatigue is a major symptom in patients with primary Sjogren's syndrome (pSS). Our aim was to investigate the importance of fatigue in relation to other symptoms experienced as well as to evaluate the effect of rituximab treatment on fatigue in pSS patients with active disease.MethodsThis analysis was based on data from our open-label rituximab study in 28 pSS patients. Symptoms of dryness, physical fatigue, pain, and mental fatigue were scored on 0-10 scales (according to ESSPRI). Systemic disease activity was assessed with ESSDAI.ResultsAt baseline, 24 (86%) patients rated physical fatigue as the complaint most eligible for improvement (median importance of 10), followed by pain, dryness, and mental fatigue. After rituximab treatment, physical fatigue showed maximum improvement of 2.5 points and 31% in median values at group level, and 10 (36%) patients reached physical fatigue score<5 representing patient-acceptable symptom state (PASS). In comparison, systemic disease activity improved 5.5 points and 73% at group level, and 22 (79%) patients reached ESSDAI<5 representing low disease activity. GEE analysis over time revealed that physical fatigue was significantly associated with absolute number of B cells, dryness and mental fatigue, but not with ESSDAI, IgG levels and IgM-RF.ConclusionPhysical fatigue characterises patient experience of pSS. Rituximab treatment resulted in significant improvement of patient-reported symptoms. However, the large majority of patients still experienced physical fatigue at an unsatisfactory level, above the cut-off value for PASS. Therefore, attention for optimal management of this prominent symptom is warranted.

AB - ObjectiveBesides ocular and oral dryness, fatigue is a major symptom in patients with primary Sjogren's syndrome (pSS). Our aim was to investigate the importance of fatigue in relation to other symptoms experienced as well as to evaluate the effect of rituximab treatment on fatigue in pSS patients with active disease.MethodsThis analysis was based on data from our open-label rituximab study in 28 pSS patients. Symptoms of dryness, physical fatigue, pain, and mental fatigue were scored on 0-10 scales (according to ESSPRI). Systemic disease activity was assessed with ESSDAI.ResultsAt baseline, 24 (86%) patients rated physical fatigue as the complaint most eligible for improvement (median importance of 10), followed by pain, dryness, and mental fatigue. After rituximab treatment, physical fatigue showed maximum improvement of 2.5 points and 31% in median values at group level, and 10 (36%) patients reached physical fatigue score<5 representing patient-acceptable symptom state (PASS). In comparison, systemic disease activity improved 5.5 points and 73% at group level, and 22 (79%) patients reached ESSDAI<5 representing low disease activity. GEE analysis over time revealed that physical fatigue was significantly associated with absolute number of B cells, dryness and mental fatigue, but not with ESSDAI, IgG levels and IgM-RF.ConclusionPhysical fatigue characterises patient experience of pSS. Rituximab treatment resulted in significant improvement of patient-reported symptoms. However, the large majority of patients still experienced physical fatigue at an unsatisfactory level, above the cut-off value for PASS. Therefore, attention for optimal management of this prominent symptom is warranted.

KW - primary Sjogren's syndrome

KW - fatigue

KW - patient-reported outcome

KW - rituximab

KW - patient-acceptable symptom state

KW - CELL DEPLETION THERAPY

KW - QUALITY-OF-LIFE

KW - REPORTED INDEX

KW - CLINICAL-TRIAL

KW - DOUBLE-BLIND

KW - DISEASE

KW - DISABILITY

KW - RITUXIMAB

KW - ESSPRI

KW - IMPROVEMENT

M3 - Article

VL - 35

SP - 255

EP - 261

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 2

ER -

ID: 41822838